Nyxoah's consensus fair value has shifted from about €5.80 to roughly €4.40, which is a reduction of close to one quarter in analyst price targets. This reset reflects recent Q2 updates, where some analysts remain encouraged by U.S. commercialization progress, while others are more cautious and prefer to wait for clearer evidence that execution can support earlier expectations. As you read on, you will see how these changing targets shape the evolving Nyxoah story and what signals to watch next.
Stay updated as the Fair Value for Nyxoah shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Nyxoah.
What Wall Street Has Been Saying
🐂 Bullish Takeaways
-
Cantor Fitzgerald cut its Nyxoah price target to US$6 from US$11 but kept an Overweight rating, which signals that Sarah James still sees appeal in the stock at current levels.
-
The firm cites Q2 U.S. commercialization progress, noting 89 new accounts and 55 surgeons added. This is presented as support for Nyxoah's stated 10% to 15% market share ambition in its segment.
🐻 Bearish Takeaways
-
Baird reduced its Nyxoah price target to US$2.31 from US$2.86 and maintains a Neutral stance, which points to a more cautious view on further upside.
-
Baird's updated model following Q2 results indicates increased focus on Nyxoah's execution and valuation, with less willingness to factor in aggressive growth assumptions without additional evidence.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there's more to the story. Head to the Simply Wall St Community to discover more perspectives!
We've flagged 4 risks for Nyxoah. See which could impact your investment.
How This Changes the Fair Value For Nyxoah
-
Consensus fair value for Nyxoah moved from about €5.80 to roughly €4.40, a reduction of close to one quarter.
-
Forecast € revenue growth moved from about 106.70% to roughly 88.19%.
-
Forecast net profit margin shifted from about 4.92% to roughly 4.35%.
-
The future P/E assumption increased from about 56.24x to roughly 105.29x.
-
The discount rate used in analyst models moved from about 6.84% to roughly 7.01%.
Never Miss an Update: Follow The Narrative
Narratives connect Nyxoah's medical and commercial story to analyst forecasts and fair value estimates in one place. They update as new clinical data, regulatory decisions, and guidance come through so you can see how the thesis is evolving.
Head over to the Simply Wall St Community and follow the Narrative on Nyxoah to stay up to date on:
-
How FDA PMA approval for the Genio system and its differentiated label could help Nyxoah reach a broader obstructive sleep apnea patient group in the U.S.
-
The role of expanding surgeon and sleep center adoption, established CPT reimbursement, and upcoming ACCCESS readouts and label expansion efforts in shaping future Genio usage.
-
Key execution risks including patent litigation, rising SG&A, reimbursement uncertainty, a restricted BMI patient pool, and cash burn that may influence dilution and long term profitability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NYXH.BR .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
